Esperion(US:ESPR)2024-05-07 12:32Financial Performance - Total revenue reached $138 million, a significant increase of 467% year-over-year[5] - US product sales, net, amounted to $25 million, representing a 46% increase year-over-year[5] Prescription Growth - Retail prescription equivalents experienced a 43% year-over-year growth[5] and 6% quarter-over-quarter growth[8] - New to Brand Rx Trends increased by 79%[29] Label Expansion and Market Access - FDA approval of new labels for NEXLETOL and NEXLIZET expands the addressable patient population to over 70 million in the US[8, 13, 19] - The new labels include indications for primary prevention and removal of the statin use qualifier[8, 11] - Utilization management criteria updates by two major payers now cover 40 million lives[9] International Expansion - Medicines Approved in 30+ Countries[33] - International growth continues with 255,000 patients through February '24[37] Financial Position - Q1 2024 cash and cash equivalents totaled $227 million[39] - FY 2024 R&D guidance is $45 - 55 million[40] - FY 2024 SG&A guidance is $180 - 190 million[40] - FY 2024 OpEx guidance is $225 - 245 million, including $20 million of non-cash stock-based compensation expense[40, 41]